Navigation Links
Rigel's R348 to Initiate Phase 2 Clinical Trial in Dry Eye
Date:5/22/2013

SOUTH SAN FRANCISCO, Calif., May 22, 2013 /PRNewswire/ -- Rigel Pharmaceuticals, Inc. (Nasdaq: RIGL) today announced the clinical advancement of three programs in development. The first program is a wholly-owned topical ophthalmic formulation of a JAK/SYK inhibitor, R348, being developed by Rigel as a treatment for dry eye disease.  The other two programs are aimed at oncology targets and are being conducted by corporate partners, including an AXL kinase inhibitor under development by BerGenBio AS (BerGenBio) and a ligase inhibitor under development by Daiichi Sankyo Company, Limited (Daiichi Sankyo). 

"Our ophthalmic formulation of R348 was shown to be well tolerated in our recent Phase 1 study and we look forward to evaluating the drug candidate in patients with chronic dry eye disorders," said Raul Rodriguez , president and chief operating officer of Rigel. "In addition, for our two partnered oncology programs, we are pleased that our partners BerGenBio and Daiichi Sankyo have each taken steps to initiate first-in-human clinical studies with small molecules that represent novel approaches to treating a variety of solid and blood borne cancers," he added.

R348, Topical Ophthalmic JAK/SYK Inhibitor
Chronic dry eye is an inflammatory disease that often affects the lacrimal (tear producing) glands of the eye.  Over five million Americans suffer with this disorder, and many patients with chronic dry eye may also suffer with autoimmune conditions, including systemic lupus erythematosus and rheumatoid arthritis.  Chronic dry eye is an irritating and painful disease that may be destructive to the cornea if not well controlled.

Rigel has developed a topical ophthalmic (eye drop) formulation of R348, a JAK/SYK inhibitor, aimed at reducing the underlying inflammation responsible for
'/>"/>

SOURCE Rigel Pharmaceuticals, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. Asubio Initiates Landmark Clinical Study in Spinal Cord Injury
2. CSL Behring Initiates Study of Subcutaneous Administration of C1-esterase Inhibitor in Patients with Hereditary Angioedema
3. Isis Initiates Phase 2 Study of ISIS-APOCIIIRx in Patients with Hypertriglyceridemia
4. Alder BioPharmaceuticals Inc. Initiates Phase 1 Clinical Study of Antibody Therapeutic Candidate for Treatment of Migraine, ALD403
5. ResMed Inc. Announces Plan To Initiate Dividend And Update On Chief Executive Officer Succession
6. Oncos Therapeutics Initiates Phase I Clinical Study of CGTG-102, an Oncolytic Adenovirus for the Treatment of Solid Tumor Cancers
7. MAQUET Initiates Class I Recall of the FLOW-i Anesthesia System
8. Stryker Initiates Voluntary Product Recall of Modular-Neck Stems
9. Inovio Initiates H1N1 Universal Influenza Vaccine Clinical Trial Targeting Over-65 Population, Which Represents 90% of Flu Deaths
10. ESTEVE Announces Publication of Key Preclinical Data for a Novel Oral, First-in-class New Chemical Entity (NCE) Sigma-1 Receptor Antagonist (E-52862), that has Completed Phase I and Initiated its Phase II Clinical Trial Program
11. Grifols Initiates Safety Study of Inhaled Alpha1-Proteinase Inhibitor (Human) Following Orphan Drug Designation for Cystic Fibrosis
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/17/2014)... 17, 2014 Research and Markets ... Cancer Market 2014-2018" report to their offering. ... growth of cancerous cells in the breast tissue. It ... cancer is rare. Histologically, breast cancer can be classified ... undifferentiated carcinoma. Ductal carcinoma is the form of breast ...
(Date:9/16/2014)... , 17. September 2014 ... ), hat heute die Markteinführung des ... Probenverarbeitung, in Europa bekannt gegeben. Der ... Universalplattform zur Vereinfachung der präanalytischen Probenverarbeitung. ... und fehlerbehaftete Arbeitsschritte bei der manuellen ...
(Date:9/16/2014)... 2014 3SBio Inc., ("3SBio") a leading ... focusing on researching, developing, manufacturing and marketing ... into an exclusive license agreement with JenKem Technology ... marketing in Mainland China of PEG-irinotecan, a long-acting ... is over-expressed in many solid tumors, including colorectal, ...
Breaking Medicine Technology:Global Breast Cancer Market 2014-2018: Key Vendors are Astrazeneca, Eli Lilly and Company and F. Hoffmann-La Roche, Novartis and Sanofi-Aventis 2Global Breast Cancer Market 2014-2018: Key Vendors are Astrazeneca, Eli Lilly and Company and F. Hoffmann-La Roche, Novartis and Sanofi-Aventis 3Hologic stellt in Europa den Tomcat vor, ein neues Gerät zur präanalytischen Probenverarbeitung 2Hologic stellt in Europa den Tomcat vor, ein neues Gerät zur präanalytischen Probenverarbeitung 33SBio Inc. obtains exclusive licenses to develop and market JenKem's PEG-Irinotecan in China 23SBio Inc. obtains exclusive licenses to develop and market JenKem's PEG-Irinotecan in China 33SBio Inc. obtains exclusive licenses to develop and market JenKem's PEG-Irinotecan in China 43SBio Inc. obtains exclusive licenses to develop and market JenKem's PEG-Irinotecan in China 5
... N.J., Oct. 27 Watson Pharmaceuticals, Inc. (NYSE: ... Laboratories, Inc., filed a new drug application under Section ... (FFDCA) with the U.S. Food and Drug Administration (FDA) ... and 40 mg tablets.  Watson,s rosuvastatin zinc tablets are ...
... Oct. 27 Intrinsic Bioprobes today announced that ... issued US Patent 7,816,095 covering novel blood protein ... first of a series of patent applications that ... clinical utility. "The biomarkers were discovered ...
Cached Medicine Technology:Watson Confirms Crestor® Patent Challenge 2Intrinsic Bioprobes Announces Issuance of US Patent for Novel Biomarkers and Assays for Myocardial Infarction 2
(Date:9/17/2014)... With the development of China’s economy, ... human body physiology, preventing diseases, promoting health, prolonging ... variety of specific populations. In 2013, the market ... billion, up 12.0% year on year, recording a ... product industry is composed of many extremely scattered ...
(Date:9/17/2014)... 2014 U.S. News and World ... country, and three mesothelioma treatment centers made the ... mesothelioma law firm Baron and Budd ... of Texas MD Anderson Cancer Center and Brigham ... ( http://health.usnews.com/best-hospitals/rankings/cancer ) , U.S. News and World ...
(Date:9/17/2014)... DMG Productions announces the upcoming airing ... broadcast on Wednesday, September 24, 2014 at 7:30 ... episode, Innovations will go behind the scenes to ... each client the opportunity to achieve the highest ... principles of Care, Compassion, and Commitment. , Audiences ...
(Date:9/17/2014)... 17, 2014 Experienced dress company, Discount-Dress.com, ... new selection of trendy black bridesmaid dresses. Furthermore, the ... its beautiful bridesmaid outfits. Readers can view more ... Discount-Dress.com is a famous brand of special ... additions as well as revamped old editions, the supplier ...
(Date:9/17/2014)... 17, 2014 Headquartered in Baltimore, Maryland, ... reach across the country. , “The past two ... “We have grown to over 400 evaluators in 46 ... evaluators in the Midwest and South Dakota and Vermont. ... facilities where our volunteers can visit.” , TPU provides ...
Breaking Medicine News(10 mins):Health News:China Health Food Industry Report 2014-2017 Now Available at ChinaMarketResearchReports.com 2Health News:China Health Food Industry Report 2014-2017 Now Available at ChinaMarketResearchReports.com 3Health News:China Health Food Industry Report 2014-2017 Now Available at ChinaMarketResearchReports.com 4Health News:Three Mesothelioma Treatment Centers Make U.S. News and World Report’s List of Top Cancer Care Facilities, Baron and Budd Reports 2Health News:Three Mesothelioma Treatment Centers Make U.S. News and World Report’s List of Top Cancer Care Facilities, Baron and Budd Reports 3Health News:Innovations to Explore Substance Abuse and Mental Health in Upcoming Episode Airing Wednesday, September 24, 2014 via Discovery Channel. 2Health News:Discount-Dress.com’s Top Designers Are Now Busy Making Its New Black Bridesmaid Dresses 2Health News:Therapy Pets Unlimited is Expanding 2Health News:Therapy Pets Unlimited is Expanding 3
... An alert over potential outbreak of 'Legionnaires Disease' has ... visited the Grand Atlantic Hotel before 10 Nov in ... samples tested positive for Legionelle Bacteria. The hotel which ... out a thorough disinfection. ,The Legionnaires disease ...
... OF HIGH BLOOD PRESSURE DOES NOT PREDICT EFFECT ON HEART ... blood pressure can lead to a potentially dangerous enlargement of ... at the Johns Hopkins Children's Center and the Children's Hospital ... not true for children, at least, that the higher the ...
... Britain has revealed that almost 59,000 Brits have an HIV ... cases were diagnosed last year. //,70 per cent of the ... Eastern Europe. Bulgaria and Romania are among the nations with ... ,It has been found that almost none of ...
... contributed to the health ratings of the famous spirit, known ... in much the same way as mice on a normal ... conducted by Harvard Scientists. ,Delving more into the ... blessings, following a second study conducted on mice. The compound ...
... fight the stigma of the disease. // ,According to ... fallen to 1.56 percent in 2005, from 14.7 percent in 2001. ... the cured are called, have been roped in since leprosy is ... in Ranchi has gone up to 1.60 percent between April and ...
... revelation, some researchers have discerned a thread of similarity ... likeness of character. //For instance, it was observed that ... had a past criminal record compared to owners of ... ,During a study of 355 dog owners in Ohio, ...
Cached Medicine News:Health News:Children and Chronic Kidney Disease 2Health News:Children and Chronic Kidney Disease 3
... developed the world's first 8-channel ... completely AC powered in 1951. ... a number of standard setting ... systems, such as a Windows ...
... you're getting an ambulatory and a clinical EEG ... Mobee O2 can be used for ambulatory EEG ... or in-lab sleep studies. And both feature 32 ... placement. The Mobee O2 includes the additional enhancement ...
... The VISULAS 690s is the ... the instrument of choice for ... clinical trials, Carl Zeiss has ... in laser manufacturing to create ...
... Humphrey Lens Analyzers Model 350 and ... most comprehensive lensometry for your practice. ... Analyzer (LA) gives fast and accurate ... lenses, prism lenses, contact lenses, polycarbonate ...
Medicine Products: